2 weeks Ago By Defense World Staff
Townsquare Capital LLC lifted its stake in Quest Diagnostics Incorporated ( NYSE:DGX – Free Report ) by 59.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,649 shares of the medical research company’s stock after acquiring an additional 990 shares during the period.
Townsquare Capital LLC’s holdings in Quest Diagnostics were worth $400,000 as of its most recent filing with the Securities and Exchange Commission. A number of other institutional investors also recently made changes to their positions in the stock. Norges Bank acquired a new stake in Quest Diagnostics in the fourth quarter worth approximately $191,823,000.
JPMorgan Chase & Co. lifted its holdings in shares of Quest Diagnostics by 60.4% in the fourth quarter.
JPMorgan Chase & Co. now owns 2,433,913 shares of the medical research company’s stock valued at $367,180,000 after buying an additional 916,898 shares during the period. Alliancebernstein L.
P. boosted its stake in Quest Diagnostics by 83.7% during the fourth quarter.
Alliancebernstein L.P. now owns 1,093,042 shares of the medical research company’s stock valued at $164,896,000 after buying an additional 497,995 shares in the last quarter.
Raymond James Financial Inc. acquired a new position in Quest Diagnostics during the fourth quarter worth about $67,447,000. Finally, Bank of New York Mellon Corp raised its position in Quest Diagnostics by 14.
8% in the fourth quarter. Bank of New York Mellon Corp now owns 881,764 shares of the medical research company’s stock worth $133,023,000 after acquiring an additional 113,956 shares in the last quarter. 88.
06% of the stock is owned by institutional investors and hedge funds. Analyst Ratings Changes DGX has been the topic of a number of research reports. Truist Financial boosted their target price on shares of Quest Diagnostics from $172.
00 to $182.00 and gave the stock a “hold” rating in a report on Friday, January 31st. Mizuho raised their price objective on Quest Diagnostics from $178.
00 to $189.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 9th. UBS Group lifted their target price on Quest Diagnostics from $166.
00 to $170.00 and gave the stock a “neutral” rating in a report on Monday, February 3rd. Piper Sandler reaffirmed a “neutral” rating and set a $180.
00 target price (up from $165.00) on shares of Quest Diagnostics in a report on Monday, February 3rd. Finally, Citigroup downgraded Quest Diagnostics from a “buy” rating to a “neutral” rating and set a $185.
00 price objective on the stock. in a report on Tuesday, March 4th. Eight equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and two have given a strong buy rating to the stock.
According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $181.33. Quest Diagnostics Trading Down 0.
4 % Quest Diagnostics stock opened at $163.75 on Monday. Quest Diagnostics Incorporated has a 12 month low of $128.
38 and a 12 month high of $178.87. The company has a quick ratio of 1.
02, a current ratio of 1.10 and a debt-to-equity ratio of 0.82.
The stock has a market cap of $18.28 billion, a P/E ratio of 21.29, a P/E/G ratio of 2.
16 and a beta of 0.78. The company’s fifty day simple moving average is $168.
62 and its 200-day simple moving average is $160.36. Quest Diagnostics ( NYSE:DGX – Get Free Report ) last issued its earnings results on Thursday, January 30th.
The medical research company reported $2.23 EPS for the quarter, beating analysts’ consensus estimates of $2.19 by $0.
04. Quest Diagnostics had a return on equity of 15.07% and a net margin of 8.
80%. As a group, sell-side analysts forecast that Quest Diagnostics Incorporated will post 9.7 EPS for the current fiscal year.
Quest Diagnostics Increases Dividend The firm also recently announced a quarterly dividend, which will be paid on Monday, April 21st. Shareholders of record on Monday, April 7th will be paid a $0.80 dividend.
The ex-dividend date is Monday, April 7th. This is a boost from Quest Diagnostics’s previous quarterly dividend of $0.75.
This represents a $3.20 dividend on an annualized basis and a yield of 1.95%.
Quest Diagnostics’s payout ratio is 41.61%. Insiders Place Their Bets In related news, SVP Karthik Kuppusamy sold 2,555 shares of the company’s stock in a transaction on Wednesday, April 2nd.
The shares were sold at an average price of $170.00, for a total value of $434,350.00.
Following the completion of the sale, the senior vice president now directly owns 10,575 shares in the company, valued at approximately $1,797,750. This represents a 19.46 % decrease in their ownership of the stock.
The sale was disclosed in a document filed with the SEC, which is accessible through this link . Also, SVP Mark E. Delaney sold 403 shares of the stock in a transaction on Wednesday, February 5th.
The stock was sold at an average price of $164.30, for a total transaction of $66,212.90.
Following the transaction, the senior vice president now directly owns 4,624 shares in the company, valued at $759,723.20. The trade was a 8.
02 % decrease in their ownership of the stock. The disclosure for this sale can be found here . Insiders sold 55,903 shares of company stock valued at $9,460,221 over the last ninety days.
Corporate insiders own 8.16% of the company’s stock. Quest Diagnostics Profile ( Free Report ) Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally.
The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. See Also Five stocks we like better than Quest Diagnostics Dividend Capture Strategy: What You Need to Know With a 60%+ Upside, There’s Plenty to Love About Lovesac Roth IRA Calculator: Calculate Your Potential Returns J.B.
Hunt Transport Overcorrects Into a Buying Opportunity Do Real Estate Investment Trusts Deserve a Place in Your Portfolio? AppLovin: Can Record Profits Overcome Market Skepticism? Want to see what other hedge funds are holding DGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Quest Diagnostics Incorporated ( NYSE:DGX – Free Report ). Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.
com's FREE daily email newsletter ..
